See What HealthDay Can Do For You
Contact Us

HAART Use Prior to Pregnancy Associated with Pre-Eclampsia

Insulin resistance, endothelial inflammation may be underlying mechanism

WEDNESDAY, Dec. 21 (HealthDay News) -- Women infected with HIV who receive highly active antiretroviral therapy (HAART) before becoming pregnant have a higher risk of pre-eclampsia and fetal death than other women, Spanish researchers report in the January issue of AIDS.

Anna Suy, M.D., and colleagues at the University of Barcelona, analyzed a database of 8,768 pregnant women from November 1985 to January 2003, which included 472 HIV-infected patients. Between January 2001 and July 2003, there were 82 HIV-infected patients, 244 cases of pre-eclampsia without fetal death, 39 cases of fetal death without pre-eclampsia and seven cases of fetal death and pre-eclampsia referred.

In all women, the odds of pre-eclampsia or fetal death was 3.6 with multiple gestation and 4.9 with HIV infection. In HIV-infected women, use of HAART prior to pregnancy was an independent risk factor (odds ratio, 5.6) for pre-eclampsia and fetal death.

The researchers conducted a case-control substudy and found that insulin resistance and endothelial inflammation may be potential underlying mechanisms linking pre-pregnancy HAART exposure and pre-eclampsia and fetal death. "If our results are confirmed, close monitoring for pre-eclampsia and fetal distress in HIV-infected pregnant women will be needed," they conclude.

Full Text (subscription or payment may be required)

Physician's Briefing


HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.